Alzinova AB
Alzinova AB is a Swedish clinical-stage biopharma company pioneering the development of an active immunotherapy against Alzheimer’s disease. The vaccine is in clinical development and tested in patients. The company’s shares (ALZ) are listed on Nasdaq First North Growth Market, Stockholm.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Nationally (across the country)
About Us
The beginnings
The company was founded by scientists at the University of Gothenburg, Sweden, in 2011 after the invention of a unique technology platform, AβCC. The AβCC technology specifically stabilises disease-driving oligomers of the peptide amyloid-β (Aβ), thus enabling the development of disease-modifying therapeutics.
Business angels and the holding company at the University of Gothenburg, GU Holding AB (now GU Ventures AB), provided seed capital and business development support during the early years.
Going public
In November 2015, Alzinova completed an IPO and was listed as a publicly traded company on Spotlight (previously ”AktieTorget”) in Sweden. In December 2018 a second round of share issuance was completed.
The new funding enabled the company to effectively move closer to clinical phase, preparing for the first clinical phase 1b study on it’s lead product, ALZ-101 – an active immunotherapy for the treatment of Alzheimer’s disease. ALZ-101 is now set to enter clinical phase 1.
Since March 2019, after completing a third capitalisation round, Alzinova is traded as a public company on the unregulated exchange list NASDAQ First North in Stockholm, Sweden (ticker: ALZ).
Our Vision
“To enable patients to live an independent and active life without any impact of Alzheimer’s disease, by developing novel disease-modifying treatments.”
Our long-term goal
Our long-term goal is to develop a disease-modifying therapeutic vaccine for the treatment and prevention of the progression of Alzheimer’s disease. A long-acting drug will make it possible for patients to lead an active and independent life without impact from the disease.